4.7 Article

Drug repositioning: Progress and challenges in drug discovery for various diseases

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 234, Issue -, Pages -

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114239

Keywords

Drug repositioning; Drug discovery; Neurological diseases; Cancer; Antimicrobial; Antiviral

Funding

  1. National Natural Science Foundation of China [81973182, 81803370]
  2. State Key Laboratory Innovation Research and Cultivation Fund [SKLNMZZ202018]
  3. Double World-classes Construction Program of China Pharmaceutical University [CPU2018GF02]

Ask authors/readers for more resources

Compared with traditional drug discovery, drug repurposing offers a cost-effective and efficient approach. Some drugs may show better effects in different diseases than their original indications. Drug repurposing has proven to be valuable, especially in addressing public health emergencies such as the COVID-19 pandemic.
Compared with traditional de novo drug discovery, drug repurposing has become an attractive drug discovery strategy due to its low-cost and high efficiency. Through a comprehensive analysis of the candidates that have been identified with drug repositioning potentials, it is found that although some drugs do not show obvious advantages in the original indications, they may exert more obvious effects in other diseases. In addition, some drugs have a synergistic effect to exert better clinical efficacy if used in combination. Particularly, it has been confirmed that drug repositioning has benefits and values on the current public health emergency such as the COVID-19 pandemic, which proved the great potential of drug repositioning. In this review, we systematically reviewed a series of representative drugs that have been repositioned for different diseases and illustrated successful cases in each disease. Especially, the mechanism of action for the representative drugs in new indications were explicitly explored for each disease, we hope this review can provide important insights for follow-up research.(c) 2022 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available